Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
Wills Eye Hospital · Houston Methodist · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
861
total citations
- FWCI
- 78.29
- Percentile
- 100%
- References
- 13
Citations per year
Authors
7Topics & keywords
Topics
Keywords
- Ranibizumab
- Medicine
- Macular degeneration
- Choroidal neovascularization
- Ophthalmology
- Adverse effect
- Visual acuity
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.